NOVAVAX INC Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
NOVAVAX INC (NVAX) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $41.90 million for the 12-month period ending 2013-12-31, per its 10-K filed 2015-02-27.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Consideration Transferred
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2016-02-29
- NOVAVAX INC business combination, consideration transferred, equity interests issued and issuable for fiscal 2013 was $41.90M.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 1 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 1 month as first filed | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 12 month |
|---|---|---|---|
| 2013-12-31 | $41.90M 10-K · filed 2015-02-27 | ||
| 2013-07-31 | $41.90M 10-K · filed 2016-02-29 | $41.94M 10-Q · filed 2013-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |